MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...

Earlier in his career, he served as CFO at multiple publicly-traded biotech companies including Sirna Therapeutics, a genetic ...

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer ...

In terms of industry tailwinds, Trump could lessen pressure from the Federal Trade Commission on mergers and acquisitions, ...

SAN ANTONIO, November 04, 2024--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to ...

Affinity Technologies (BIAF) announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in ...

A total of 27 analyst ratings have been received for Biomarin Pharmaceutical, with the consensus rating being Outperform. The average one-year price target stands at $100.85, suggesting a potential 44 ...

About Sanofi/Novartis litigation On March 30,2022, MediciNova, Inc. was notified that Genzyme Corporation, a subsidiary of Sanofi, filed its First Amended Complaint, which included a claim for ...

Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...